Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 424 participants.
Also called NCT04373967
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 424 participants
- Registry
-
NCT04373967
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04373967. Randomized; no masking; primary purpose treatment. Start 2020-04-29 (actual); primary completion 2021-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Victoza®.
- Intervention (Drug)
- Metformin Hydrochloride
- Intervention (Drug)
- TQZ2451
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Record details
- Record id
cardio:ct-nct04373967- Content hash
d13073b0f3e7646487287973468b17de60c8b53a8cc63a4e2f5d6f043d14a305